Literature DB >> 25643196

Giant cell myocarditis successfully treated with antithymocyte globuline and extracorporeal membrane oxygenation for 21 days.

Enrico Ammirati1, Fabrizio Oliva, Oriana Belli, Edgardo Bonacina, Patrizia Pedrotti, Fabio Maria Turazza, Alberto Roghi, Roberto Paino, Luigi Martinelli, Maria Frigerio.   

Abstract

: A 31-year-old man presenting with cardiogenic shock and left ventricular ejection fraction of 10% received the diagnosis of giant cell myocarditis by endomyocardial biopsy. The patient was successfully treated with high-dose inotropes, intra-aortic balloon pump and venoarterial extracorporeal membrane oxygenation for 21 days associated with combined immunosuppression (thymoglobulin, steroids, cyclosporine). Immunosuppression including thymoglobulin is the regimen associated with the highest probability of recovery in case of giant cell myocarditis. Immunosuppression needs time to be effective; thus, hemodynamic support must be guaranteed. In the present case, we observed that full recovery can be obtained up to 21 days of support with extracorporeal membrane oxygenation and adequate immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25643196     DOI: 10.2459/JCM.0000000000000250

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  6 in total

Review 1.  Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment.

Authors:  Enrico Ammirati; Giacomo Veronese; Manlio Cipriani; Francesco Moroni; Andrea Garascia; Michela Brambatti; Eric D Adler; Maria Frigerio
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

2.  Hemodynamic Transesophageal Echocardiography-Guided Venous-Arterial Extracorporeal Membrane Oxygenation Support in a Case of Giant Cell Myocarditis.

Authors:  Juan G Ripoll; Robert A Ratzlaff; David M Menke; Maria C Olave; Joseph J Maleszewski; José L Díaz-Gómez
Journal:  Case Rep Crit Care       Date:  2016-08-25

3.  Fulminant myocarditis: Characteristics, treatment, and outcomes.

Authors:  Giacomo Veronese; Enrico Ammirati; Manlio Cipriani; Maria Frigerio
Journal:  Anatol J Cardiol       Date:  2018-03-13       Impact factor: 1.596

Review 4.  Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges.

Authors:  Roberto Martin Huertas; Cristina Saavedra Serrano; Cristian Perna; Ana Ferrer Gómez; Teresa Alonso Gordoa
Journal:  Cancer Manag Res       Date:  2019-05-16       Impact factor: 3.989

5.  Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.

Authors:  Enrico Ammirati; Emanuele Bizzi; Giacomo Veronese; Matthieu Groh; Caroline M Van de Heyning; Jukka Lehtonen; Marc Pineton de Chambrun; Alberto Cereda; Chiara Picchi; Lucia Trotta; Javid J Moslehi; Antonio Brucato
Journal:  Front Med (Lausanne)       Date:  2022-03-07

6.  Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.

Authors:  Enrico Ammirati; Maria Frigerio; Leslie T Cooper; Paolo G Camici; Eric D Adler; Cristina Basso; David H Birnie; Michela Brambatti; Matthias G Friedrich; Karin Klingel; Jukka Lehtonen; Javid J Moslehi; Patrizia Pedrotti; Ornella E Rimoldi; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Circ Heart Fail       Date:  2020-11-12       Impact factor: 8.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.